Drug Companies Poised to Cash in on Obamacares Coverage Expansion
![](/46/pdcnewsitem/03/28/16/8rbDRtjhXnUMWIS.jpg)
Despite the noteworthy criticism that the Affordable Care Act (ACA) is attracting, pharmaceutical companies will have something to cheer about as the sale of prescription drugs is expected to skyrocket by 2021, says an analyst with research and consulting firm GlobalData.
Prior to the implementation of Obamacare, the total value of pharmaceutical products consumed in the US (prescription drugs and non-durable medical equipment only) was approximately $300 billion in 2009 — close to a global market share of 40%, according to GlobalData.
The company now expects the total value of pharmaceutical products to grow by a massive 88.6% to $565.2 billion by 2021, with prescription drugs accounting for approximately 85.5% ($483 billion) of these expenditures, as a result of implementation of the ACA’s provisions.
Adefemi Adenuga, GlobalData’s Analyst covering Healthcare Industry Dynamics, says: “This signifies a considerable payday for drug companies in the US market, particularly those developing and marketing prescription drugs for chronic and age-related diseases.”
The key drivers of this additional growth are the expected increase in the volume of individual and group insurance coverage, as well as coverage-related expansions, particularly of government programmes such as Medicaid.
Adenuga continues: “The implementation of the ACA’s provisions will result in an explosion in prescription drug spending, especially on products that treat high prescription volume diseases, such as pain, high cholesterol and blood pressure, anxiety and depression.”
Although drug manufacturers are faced with new fees and taxes, Adenuga says that the potential surge in sales presents a trade-off that is hard to ignore.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance